Infinity Pharmaceuticals, Inc. - Product Pipeline Review - 2012

Summary

“Infinity Pharmaceuticals, Inc. - Product Pipeline Review - 2012” provides data on the Infinity Pharmaceuticals, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Infinity Pharmaceuticals, Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from Infinity Pharmaceuticals, Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Infinity Pharmaceuticals, Inc. - Brief Infinity Pharmaceuticals, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Infinity Pharmaceuticals, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Infinity Pharmaceuticals, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Infinity Pharmaceuticals, Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Infinity Pharmaceuticals, Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Infinity Pharmaceuticals, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Infinity Pharmaceuticals, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Infinity Pharmaceuticals, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Infinity Pharmaceuticals, Inc. and identify potential opportunities in those areas.

Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Infinity Pharmaceuticals, Inc. Snapshot 7
Infinity Pharmaceuticals, Inc. Overview 7
Key Information 7
Key Facts 7
Infinity Pharmaceuticals, Inc. – Research and Development Overview 8
Key Therapeutic Areas 8
Infinity Pharmaceuticals, Inc. – Pipeline Review 11
Pipeline Products by Stage of Development 11
Pipeline Products – Monotherapy 12
Pipeline Products – Combination Treatment Modalities 13
Infinity Pharmaceuticals, Inc. – Pipeline Products Glance 14
Infinity Pharmaceuticals, Inc. Clinical Stage Pipeline Products 14
Phase II Products/Combination Treatment Modalities 14
Phase I Products/Combination Treatment Modalities 15
Infinity Pharmaceuticals, Inc. – Early Stage Pipeline Products 16
Pre-Clinical Products/Combination Treatment Modalities 16
Infinity Pharmaceuticals, Inc. – Drug Profiles 17
IPI-145 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
IPI-504 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
IPI-504 + Everolimus 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
IPI-504 + Rapamycin 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
IPI-504 + Taxotere 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
IPI-926 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
IPI-926 + Abraxane 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
IPI-926 + Gemcitabine 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
IPI-940 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
PI3K Delta And Gamma Inhibitor 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Infinity Pharmaceuticals, Inc. – Pipeline Analysis 30
Infinity Pharmaceuticals, Inc. – Pipeline Products by Therapeutic Class 30
Infinity Pharmaceuticals, Inc. – Pipeline Products By Target 31
Infinity Pharmaceuticals, Inc. – Pipeline Products by Route of Administration 32
Infinity Pharmaceuticals, Inc. – Pipeline Products By Mechanism of Action 33
Infinity Pharmaceuticals, Inc. – Recent Pipeline Updates 35
Infinity Pharmaceuticals, Inc. - Dormant Projects 39
Infinity Pharmaceuticals, Inc. - Discontinued Pipeline Products 40
Discontinued Pipeline Product Profiles 40
IPI-926 40
Infinity Pharmaceuticals, Inc. – Company Statement 41
Infinity Pharmaceuticals, Inc. – Locations And Subsidiaries 42
Head Office 42
Other Locations & Subsidiaries 42
Infinity Pharmaceuticals, Inc., Recent Developments 43
Infinity Pharmaceuticals, Inc.- Press Release 43
Jun 27, 2012: Infinity Pharma Reports Preclinical Data For IPI-145 43
Jun 18, 2012: Infinity Pharma Stops Phase II Trials Of Saridegib In Chondrosarcoma And Myelofibrosis 44
Apr 01, 2012: Infinity Reports New Preclinical Data For Saridegib At AACR Supporting Development In Residual Disease Settings 45
Jan 27, 2012: Infinity Stops Phase II Study Of Saridegib Plus Gemcitabine In Patients With Metastatic Pancreatic Cancer 46
Jan 20, 2012: Infinity Reports New Data From Phase Ib Trial Of Saridegib In Patients With Pancreatic Cancer At ASCO-GI 47
Jul 23, 2009: Infinity Paper On Discovery Of Its Novel Hedgehog Inhibitor, IPI-926, Published in Journal of Medicinal Chemistry. 48
May 30, 2009: Infinity Reports Encouraging Clinical Data For IPI-504 At ASCO 2009 49
May 30, 2009: Infinity Reports Encouraging Clinical Data For IPI-504 At ASCO 2009 50
May 29, 2009: Preclinical Data Show Anti-Tumor Activity by IPI-926 In Combination With Gemcitabine. 51
Apr 21, 2009: Infinity Presents Preclinical Data Demonstrating Potential Of Hedgehog Pathway Inhibition With IPI-926 In Multiple Cancer Settings 52
Apr 08, 2009: Infinity To Present Preclinical Data From Its Hsp90 Inhibitor Program And Its Hedgehog Signaling Pathway Inhibitor Program At AACR Meeting 52
Mar 30, 2009: Infinity Initiates International Phase II Trial Of IPI-504 In Combination With Herceptin In Patients With HER2-Positive Breast Cancer 53
Feb 09, 2009: Infinity Announces Hedgehog Pathway Preclinical Data In Ovarian Cancer. 54
Jan 08, 2009: Infinity Announces Completion Of Second Equity Investment By Purdue 54
Financial Deals Landscape 56
Infinity Pharmaceuticals, Inc., Deals Summary 56
Infinity Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deal Details 59
Asset Transactions 59
Infinity Pharma Re-Acquires Rights Of Hsp90 Program From MedImmune 59
Infinity Pharma Reacquires Rights of Hedgehog Pathway Program 61
Partnerships 63
Infinity Pharma Extends Co-Development Agreement With Mundipharma 63
Infinity Pharma Extends Its Collaboration Agreement With Mundipharma International 65
Mundipharma International And Purdue Pharma Exercises Rights To Infinity's FAAH Program 67
Infinity Pharma Enters Into Collaboration Agreement With Mundipharma And Purdue Pharma 69
MedImmune Enters Into Agreement With Infinity Pharma 71
Infinity Pharma Enters Into Collaboration Agreement With Novartis 73
Discovery Partners Enters Into Co-Development Agreement With Mitsubishi Pharma 75
Discovery Partners Enters Into Collaboration With Ono Pharma 76
Sareum Enters Into An Agreement With Infinity Pharma 77
NascaCell Enters Into Co-Marketing Agreement With Discovery Partners 78
Biovitrum Enters Into Research Agreement With Discovery Partners 79
TheraSTrat Enters Into Agreement With Discovery Partners 80
Infinity Pharma Enters Into Collaboration Agreement With Novartis 81
Discovery Partners International Enters Into An Agreement With Vertex 82
Discovery Partners Enters Into Drug Discovery Collaboration With Chroma Therapeutics 83
Infinity Pharma Enters Into Collaboration Agreement With Pfizer 84
Discovery Partners International Enters Into An Agreement With Pfizer 85
Discovery Partners International Enters Into A Research Agreement With Celltech 86
Merger 87
Discovery Partners International Merges With Infinity Pharma 87
Licensing Agreements 88
Infinity Pharma Enters Into Licensing Agreement With BioImage 88
Infinity Pharma Enters Into License Agreement With Intellikine 89
Horizon Discovery Enters Into Licensing Agreement With Infinity Pharma 91
Infinity Pharma Enters Into Licensing Agreement With Amgen 92
Infinity Pharma Amends Licensing Agreement With Johnson & Johnson 93
Infinity Pharma Enters Into Agreement With Johnson & Johnson 94
Equity Offering 95
Infinity Pharma Files Registration Statement For Public Offering Of $100 Million 95
Infinity Pharma Completes Second Equity Financing Of $30 Million 97
Asset Transactions 99
Infinity Pharma Sells Its Discovery Systems Business To Nexus Biosystems 99
Acquisition 101
Galapagos Acquires Discovery Partners, ChemRx, Xenometrix And Discovery Partners International From Infinity 101
Infinity Pharma Acquires Biofrontera Discovery From Biofrontera 103
Appendix 105
Methodology 105
Coverage 105
Secondary Research 105
Primary Research 105
Expert Panel Validation 105
Contact Us 106
Disclaimer 106

List of Tables
Infinity Pharmaceuticals, Inc., Key Information 7
Infinity Pharmaceuticals, Inc., Key Facts 7
Infinity Pharmaceuticals, Inc. – Pipeline by Indication, 2012 10
Infinity Pharmaceuticals, Inc. – Pipeline by Stage of Development, 2012 11
Infinity Pharmaceuticals, Inc. – Monotherapy Products in Pipeline, 2012 12
Infinity Pharmaceuticals, Inc. – Combination Treatment Modalities in Pipeline, 2012 13
Infinity Pharmaceuticals, Inc. – Phase II, 2012 14
Infinity Pharmaceuticals, Inc. – Phase I, 2012 15
Infinity Pharmaceuticals, Inc. – Pre-Clinical, 2012 16
Infinity Pharmaceuticals, Inc. – Pipeline By Therapeutic Class, 2012 30
Infinity Pharmaceuticals, Inc. - Pipeline By Target, 2012 31
Infinity Pharmaceuticals, Inc. – Pipeline By Route of Administration, 2012 32
Infinity Pharmaceuticals, Inc. – Pipeline Products By Mechanism of Action, 2012 34
Infinity Pharmaceuticals, Inc. – Recent Pipeline Updates, 2012 35
Infinity Pharmaceuticals, Inc. - Dormant Developmental Projects,2012 39
Infinity Pharmaceuticals, Inc. - Discontinued Pipeline Products, 2012 40
Infinity Pharmaceuticals, Inc., Subsidiaries 42
Infinity Pharmaceuticals, Inc., Deals Summary 56
Infinity Pharma Re-Acquires Rights Of Hsp90 Program From MedImmune 59
Infinity Pharma Reacquires Rights of Hedgehog Pathway Program 61
Infinity Pharma Extends Co-Development Agreement With Mundipharma 63
Infinity Pharma Extends Its Collaboration Agreement With Mundipharma International 65
Mundipharma International And Purdue Pharma Exercises Rights To Infinity's FAAH Program 67
Infinity Pharma Enters Into Collaboration Agreement With Mundipharma And Purdue Pharma 69
MedImmune Enters Into Agreement With Infinity Pharma 71
Infinity Pharma Enters Into Collaboration Agreement With Novartis 73
Discovery Partners Enters Into Co-Development Agreement With Mitsubishi Pharma 75
Discovery Partners Enters Into Collaboration With Ono Pharma 76
Sareum Enters Into An Agreement With Infinity Pharma 77
NascaCell Enters Into Co-Marketing Agreement With Discovery Partners 78
Biovitrum Enters Into Research Agreement With Discovery Partners 79
TheraSTrat Enters Into Agreement With Discovery Partners 80
Infinity Pharma Enters Into Collaboration Agreement With Novartis 81
Discovery Partners International Enters Into An Agreement With Vertex 82
Discovery Partners Enters Into Drug Discovery Collaboration With Chroma Therapeutics 83
Infinity Pharma Enters Into Collaboration Agreement With Pfizer 84
Discovery Partners International Enters Into An Agreement With Pfizer 85
Discovery Partners International Enters Into A Research Agreement With Celltech 86
Discovery Partners International Merges With Infinity Pharma 87
Infinity Pharma Enters Into Licensing Agreement With BioImage 88
Infinity Pharma Enters Into License Agreement With Intellikine 89
Horizon Discovery Enters Into Licensing Agreement With Infinity Pharma 91
Infinity Pharma Enters Into Licensing Agreement With Amgen 92
Infinity Pharma Amends Licensing Agreement With Johnson & Johnson 93
Infinity Pharma Enters Into Agreement With Johnson & Johnson 94
Infinity Pharma Files Registration Statement For Public Offering Of $100 Million 95
Infinity Pharma Completes Second Equity Financing Of $30 Million 97
Infinity Pharma Sells Its Discovery Systems Business To Nexus Biosystems 99
Galapagos Acquires Discovery Partners, ChemRx, Xenometrix And Discovery Partners International From Infinity 101
Infinity Pharma Acquires Biofrontera Discovery From Biofrontera 103

List of Figures
Infinity Pharmaceuticals, Inc. – Pipeline by Indication, 2012 9
Infinity Pharmaceuticals, Inc. – Pipeline by Stage of Development, 2012 11
Infinity Pharmaceuticals, Inc. – Monotherapy Products in Pipeline, 2012 12
Infinity Pharmaceuticals, Inc. – Combination Treatment Modalities in Pipeline, 2012 13
Infinity Pharmaceuticals, Inc. – Pipeline By Therapeutic Class, 2012 30
Infinity Pharmaceuticals, Inc. - Pipeline By Target, 2012 31
Infinity Pharmaceuticals, Inc. – Pipeline By Route of Administration, 2012 32
Infinity Pharmaceuticals, Inc. - Pipeline Products By Mechanism of Action, 2012 33